Cancer Screening and Genetic Services for Breast and Colon Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests new methods to improve screening for both breast and colon cancer. It examines whether combining assistance for both screenings and providing education about genetic services enhances the process for patients. The trial targets Black or Hispanic/Latina women, aged 45 to 74, who require both breast and colon cancer screenings and use specific cancer centers for these services. As an unphased trial, it presents a unique opportunity to enhance cancer screening processes and access to genetic education for underserved communities.
Do I have to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.
What prior data suggests that this bundled cancer screening and genetic services navigation is safe?
In a previous study, researchers tested the effectiveness of combining cancer screenings and genetic services, focusing on breast and colon cancer screenings.
Specific safety information isn't available, but this type of study is usually labeled "Not Applicable" for phase. This is because it doesn't test a drug or device that might cause side effects; instead, it examines the process of screening and education.
Other studies on similar screening methods have not reported safety issues. Since these services involve screenings and education, they are generally considered safe and manageable. There have been no reports of problems caused by the screenings themselves.
Overall, this combined approach appears to be a safe way to help people understand their cancer risk and the importance of regular screenings.12345Why are researchers excited about this trial?
Researchers are excited about these services because they offer a comprehensive approach to cancer screening and genetic services that could significantly enhance early detection and personalized care. Unlike the standard of care, which often involves separate and sequential steps for screening and genetic counseling, this approach bundles these services with navigation support. This integration not only streamlines the process but also provides patients with pre-test education and navigation through multicancer screening options, potentially leading to more timely interventions and better outcomes. By combining these elements, this method aims to improve patient engagement and adherence, ultimately optimizing the screening and prevention landscape for breast and colon cancer.
What evidence suggests that this trial's treatments could be effective for breast and colon cancer?
This trial will evaluate different approaches to cancer screening and genetic services for breast and colon cancer. Studies have shown that combining screenings for breast and colorectal cancers can increase the number of people getting tested. For example, one study found that 38.7% of participants completed both tests when offered enhanced care options. This method is gaining popularity because it allows individuals to be screened for multiple cancers simultaneously. The combined services also include genetic counseling, which helps individuals understand their cancer risks based on family history. This is crucial because knowing one's risk can lead to early detection or even prevention of cancer. Participants in this trial will be assigned to different arms, such as usual care breast cancer screening navigation or multicancer screening navigation, with some arms also including genetic referral and pretest education.13467
Are You a Good Fit for This Trial?
This trial is for individuals at risk of breast and colon cancer due to genetic susceptibility. It's designed to assess the effectiveness of bundled familial cancer risk assessment and navigation services for multiple cancers compared to single-cancer navigation or usual care.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment and Randomization
Research staff obtain consent and HIPAA authorization, proceeding with baseline assessment and randomization, stratified by site and genetics eligibility.
Navigation
Participants receive either multicancer or single cancer navigation, with a wait list control for colorectal cancer screening referral and navigation.
Follow-up
Participants are monitored for receipt of colorectal and breast cancer screenings, as well as genetic testing and counseling.
What Are the Treatments Tested in This Trial?
Interventions
- Bundled Cancer Screening and Genetic Services Navigation
Find a Clinic Near You
Who Is Running the Clinical Trial?
Georgetown University
Lead Sponsor
National Cancer Institute (NCI)
Collaborator